Dong-A St (170900) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.003x

Based on the latest financial reports, Dong-A St (170900) has a cash flow conversion efficiency ratio of 0.003x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.99 Billion ≈ $1.35 Million USD) by net assets (₩671.65 Billion ≈ $455.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 170900 market cap for the company's overall valuation and market capitalisation.

Dong-A St - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Dong-A St's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Dong-A St Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Dong-A St ranked by their cash flow conversion efficiency. Explore Dong-A St (170900) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Dimerco Data System
TWO:5403
-0.004x
QORIA Ltd
AU:QOR
-0.050x
NACCO Industries Inc
NYSE:NC
0.028x
X3 Acquisition Corp. Ltd. Class A Ordinary Shares
NASDAQ:XCBE
-0.001x
Automatic Bank Services Ltd
TA:SHVA
0.086x
Chongqing Machinery & Electric Co. Ltd
F:CE3
0.001x
Mkango Resources Ltd
V:MKA
-0.145x
Kogan.com Ltd
AU:KGN
-0.163x

Annual Cash Flow Conversion Efficiency for Dong-A St (2013–2025)

The table below shows the annual cash flow conversion efficiency of Dong-A St from 2013 to 2025. View 170900 stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩671.65 Billion
≈ $455.17 Million
₩27.78 Billion
≈ $18.83 Million
0.041x +348.74%
2024-12-31 ₩708.81 Billion
≈ $480.35 Million
₩-11.79 Billion
≈ $-7.99 Million
-0.017x -436.74%
2023-12-31 ₩683.31 Billion
≈ $463.07 Million
₩3.37 Billion
≈ $2.29 Million
0.005x -89.64%
2022-12-31 ₩690.11 Billion
≈ $467.68 Million
₩32.89 Billion
≈ $22.29 Million
0.048x -36.63%
2021-12-31 ₩656.38 Billion
≈ $444.82 Million
₩49.37 Billion
≈ $33.46 Million
0.075x +78.68%
2020-12-31 ₩642.10 Billion
≈ $435.14 Million
₩27.03 Billion
≈ $18.32 Million
0.042x -51.67%
2019-12-31 ₩645.86 Billion
≈ $437.69 Million
₩56.25 Billion
≈ $38.12 Million
0.087x +0.65%
2018-12-31 ₩579.36 Billion
≈ $392.63 Million
₩50.14 Billion
≈ $33.98 Million
0.087x -1.83%
2017-12-31 ₩581.19 Billion
≈ $393.87 Million
₩51.23 Billion
≈ $34.72 Million
0.088x +2648.88%
2016-12-31 ₩589.22 Billion
≈ $399.31 Million
₩1.89 Billion
≈ $1.28 Million
0.003x -95.81%
2015-12-31 ₩553.77 Billion
≈ $375.28 Million
₩42.40 Billion
≈ $28.73 Million
0.077x -55.88%
2014-12-31 ₩488.34 Billion
≈ $330.94 Million
₩84.75 Billion
≈ $57.43 Million
0.174x +546.86%
2013-12-31 ₩439.36 Billion
≈ $297.75 Million
₩-17.06 Billion
≈ $-11.56 Million
-0.039x --

About Dong-A St

KO:170900 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$225.15 Million
₩332.23 Billion KRW
Market Cap Rank
#16196 Global
#582 in Korea
Share Price
₩34450.00
Change (1 day)
-1.15%
52-Week Range
₩32000.00 - ₩57800.00
All Time High
₩155894.20
About

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bl… Read more